1150 related articles for article (PubMed ID: 31064820)
21. LncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling.
Sun Y; Song Y; Liu C; Geng J
Biochem Biophys Res Commun; 2019 Aug; 516(2):584-590. PubMed ID: 31239155
[TBL] [Abstract][Full Text] [Related]
22. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway.
Chen Y; Chen X; Gao J; Xu C; Xu P; Li Y; Zhu Y; Yu C
FASEB J; 2019 Oct; 33(10):11411-11419. PubMed ID: 31311301
[TBL] [Abstract][Full Text] [Related]
23. miR-3666 inhibits development of hepatic steatosis by negatively regulating PPARγ.
Mittal S; Inamdar S; Acharya J; Pekhale K; Kalamkar S; Boppana R; Ghaskadbi S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Oct; 1865(10):158777. PubMed ID: 32755726
[TBL] [Abstract][Full Text] [Related]
24. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
[TBL] [Abstract][Full Text] [Related]
25. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
[TBL] [Abstract][Full Text] [Related]
27. Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway.
Jin SS; Lin CJ; Lin XF; Zheng JZ; Guan HQ
Ann Hepatol; 2022; 27(2):100584. PubMed ID: 34808393
[TBL] [Abstract][Full Text] [Related]
28. miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1.
Liu XL; Cao HX; Wang BC; Xin FZ; Zhang RN; Zhou D; Yang RX; Zhao ZH; Pan Q; Fan JG
World J Gastroenterol; 2017 Dec; 23(46):8140-8151. PubMed ID: 29290651
[TBL] [Abstract][Full Text] [Related]
29. Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor γ in Mice.
Tong J; Han CJ; Zhang JZ; He WZ; Zhao GJ; Cheng X; Zhang L; Deng KQ; Liu Y; Fan HF; Tian S; Cai J; Huang Z; She ZG; Zhang P; Li H
Hepatology; 2019 Jun; 69(6):2471-2488. PubMed ID: 30748020
[TBL] [Abstract][Full Text] [Related]
30. Suppression of miR-30a-3p Attenuates Hepatic Steatosis in Non-alcoholic Fatty Liver Disease.
Wang DR; Wang B; Yang M; Liu ZL; Sun J; Wang Y; Sun H; Xie LJ
Biochem Genet; 2020 Oct; 58(5):691-704. PubMed ID: 32419060
[TBL] [Abstract][Full Text] [Related]
31. RMRP inhibition prevents NAFLD progression in rats via regulating miR-206/PTPN1 axis.
Yin J; Chen X; Zhang F; Zhao M
Mamm Genome; 2022 Sep; 33(3):480-489. PubMed ID: 35141790
[TBL] [Abstract][Full Text] [Related]
32. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
[TBL] [Abstract][Full Text] [Related]
33. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
34. ZNF143 inhibits hepatocyte mitophagy and promotes non-alcoholic fatty liver disease by targeting increased lncRNA NEAT1 expression to activate ROCK2 pathway.
Dong Y; Hu M; Tan K; Dai R
Epigenetics; 2023 Dec; 18(1):2239592. PubMed ID: 37566742
[TBL] [Abstract][Full Text] [Related]
35. Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARγ expression.
Li L; Fu J; Liu D; Sun J; Hou Y; Chen C; Shao J; Wang L; Wang X; Zhao R; Wang H; Andersen ME; Zhang Q; Xu Y; Pi J
Redox Biol; 2020 Feb; 30():101412. PubMed ID: 31901728
[TBL] [Abstract][Full Text] [Related]
36. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
37. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model.
Im AR; Kim YH; Lee HW; Song KH
J Med Food; 2016 May; 19(5):495-503. PubMed ID: 27152979
[TBL] [Abstract][Full Text] [Related]
38. LncRNA HOTAIR regulates the lipid accumulation in non-alcoholic fatty liver disease via miR-130b-3p/ROCK1 axis.
Guo B; Cheng Y; Yao L; Zhang J; Lu J; Qi H; Chen H
Cell Signal; 2022 Feb; 90():110190. PubMed ID: 34774989
[TBL] [Abstract][Full Text] [Related]
39. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
[TBL] [Abstract][Full Text] [Related]
40. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
